跳至主要内容
临床试验/NCT00729235
NCT00729235已完成4 期

Biventricular Tachycardias Outcome Trial

LivaNova74 个研究点 分布在 9 个国家目标入组 481 人开始时间: 2006年5月最近更新:
适应症
干预措施

试验速览

阶段
4 期
状态
已完成
发起方
LivaNova
入组人数
481
试验地点
74
主要终点
Incidence of slow ventricular tachycardias (Slow VTs) in CRT-ICD pts;

研究概览

简要总结

This clinical investigation is a device-based open, prospective, multicenter two-arm randomized trial, comparing patients who are treated in the slow VT zone versus patients who are not treated in that zone.

The device intended to be used is the OVATIOTM CRT model 6750 but future generation of Sorin Group/ ELA Medical devices may be used provided they are CE marked. Ethics committees and health authorities will be informed prior to any use of a newer device if applicable.

All patients will have a 3-zone detection configuration programmed. The slow VT zone will be defined by programming the detection parameters as follows:

  • Slow VT detection rate: 100 bpm (or if the resting rate is higher than 80 bpm, we recommend to adjust this parameter to: resting rate + 30 bpm)
  • VT detection rate: 150 bpm

PARAD+ will be the first choice for SVT/ST and VT discrimination in the VT zones.

The Fast VT and VF limits are left to investigator's judgment. Therapy on VT, fast VT and VF are also left to the investigator's judgment.

Patients will be randomized at implant to have the slow VT zone programmed as a monitoring zone (monitoring arm) or to have therapies programmed within the slow VT zone (therapy arm). The randomization table will be generated by Sorin Group/ELA Medical.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Single (Participant)

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Patient has been prescribed the implantation or replacement of a CRT-ICD system accordingly to the relevant currently-approved ACC/AHA15 (August 2005, Appendix §M.10) or ESC 16 (Update 2005, Appendix § M.11) guidelines or any relevant currently-approved local guidelines for the implantation or replacement of CRT-ICD.
  • Patient has signed a consent form after he/she received the appropriate and mandatory information.

排除标准

  • Clinical history of symptomatic or not symptomatic slow VT;
  • Permanent Atrial Fibrillation (AF);
  • Any contraindication to the implant or replacement of CRT-ICD;
  • Pt is unable to attend the scheduled f-up visits at the implanting Centre;
  • Pt is already included in another ongoing clinical study;
  • Pt is unable to understand the objectives of the ITAC04 study;
  • Pt refuses to cooperate;
  • Pt is unable or refuses to provide informed consent;
  • Pt is minor (less than 18-year old);
  • Pt has life expectancy of less than 1 year;
  • Pt is pregnant.

研究组 & 干预措施

1

Experimental

Slow VT zone programmed as a "Monitoring" zone (Monitoring arm)

干预措施: Ovatio CRT 6750 (Device)

2

Experimental

Slow VT zone programmed with ATP therapies (therapy arm).

干预措施: Ovatio CRT 6750 (Device)

结局指标

主要结局

Incidence of slow ventricular tachycardias (Slow VTs) in CRT-ICD pts;

时间窗: 24 months

ATP therapy efficacy on slow VTs conversion.

时间窗: 24 months

次要结局

  • Efficacy of ATP therapies on Slow VTs according to therapy setting (delivery in LV only, in RV only, or in LV+RV)(24 months)
  • Tvar risk stratification(24 months)
  • "unscheduled visits" or "hospital re-admissions" due to slow VTs;(24 months)
  • Incidence of adverse events (AEs) in the studied population(24 months)

研究者

发起方
LivaNova
申办方类型
Industry

研究点 (74)

Loading locations...

相似试验